The estimated Net Worth of Robert K Zeldin is at least 435 千$ dollars as of 14 January 2024. Dr Zeldin owns over 37,500 units of MeiraGTx plc stock worth over 434,637$ and over the last 6 years he sold MGTX stock worth over 0$.
Dr has made over 4 trades of the MeiraGTx plc stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 37,500 units of MGTX stock worth 156,000$ on 14 January 2024.
The largest trade he's ever made was exercising 75,000 units of MeiraGTx plc stock on 14 January 2023 worth over 312,000$. On average, Dr trades about 13,864 units every 54 days since 2018. As of 14 January 2024 he still owns at least 104,480 units of MeiraGTx plc stock.
You can see the complete history of Dr Zeldin stock trades at the bottom of the page.
Dr. Robert K. Zeldin M.D. is the Chief Medical Officer at MeiraGTx plc.
Dr D is 58, he's been the Chief Medical Officer of MeiraGTx plc since . There are 8 older and 8 younger executives at MeiraGTx plc. The oldest executive at MeiraGTx Holdings plc is Arnold Levine, 80, who is the Independent Director.
Robert's mailing address filed with the SEC is 450 EAST 29TH STREET, 14TH FLOOR, NEW YORK, NY, 10016.
Over the last 6 years, insiders at MeiraGTx plc have traded over 7,031,523$ worth of MeiraGTx plc stock and bought 9,222,038 units worth 85,317,799$ . The most active insiders traders include Advisors Llcperceptive Life...、Joel S Marcus、Life Sciences Master Fund L.... On average, MeiraGTx plc executives and independent directors trade stock every 33 days with the average trade being worth of 672,044$. The most recent stock trade was executed by Advisors Llcperceptive Life... on 12 August 2024, trading 1,250,000 units of MGTX stock currently worth 5,000,000$.
meiragtx, a london and new york-based gene therapy company, is committed to the development of novel gene therapies to transform the lives of patients suffering from acquired and inherited disorders. we are pioneering the use of gene therapy to treat devastating neurodegenerative diseases such as alzheimer’s disease (ad), parkinson’s disease (pd), and amyotrophic lateral sclerosis (als). we are developing innovative gene therapies for ocular diseases including rare inherited blindness and age-related macular degeneration (amd). meiragtx is also establishing treatments for xerostomia, a frequent and debilitating side effect of radiation treatment used in head and neck cancers. our revolutionary gene regulation technologies promise to transform the way gene therapy can be applied and create new paradigms for biologic therapeutics.
MeiraGTx plc executives and other stock owners filed with the SEC include: